Indication
For the treatment of adult patients with small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Medicine details
- Medicine name:
- tarlatamab (Imdylltra)
- SMC ID:
- SMC2993
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC